How to buy Alnylam Pharmaceuticals stock | $141.99

Alnylam Pharmaceuticals, Inc is a biotechnology business based in the US. Alnylam Pharmaceuticals shares (ALNY) are listed on the NASDAQ and all prices are listed in US Dollars. Alnylam Pharmaceuticals employs 1,453 staff and has a trailing 12-month revenue of around 0.00.

Alnylam Pharmaceuticals stock price (NASDAQ: ALNY)

Use our graph to track the performance of ALNY stocks over time.

Alnylam Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-07-30.

Latest market close	$141.99
52-week range	$119.29 - $184.45
50-day moving average	$173.47
200-day moving average	$152.81
Wall St. target price	$174.78
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-8.25

Buy Alnylam Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Alnylam Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Alnylam Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alnylam Pharmaceuticals price performance over time

Historical closes compared with the close of $141.99 from 2021-05-28

1 week (2021-07-24)	N/A
1 month (2021-07-02)	-17.17%
3 months (2021-05-04)	7.92%
6 months (2021-01-31)	N/A

1 year (2020-07-31)	N/A
2 years (2019-07-31)	N/A
3 years (2018-07-31)	N/A
5 years (2016-07-31)	N/A

Alnylam Pharmaceuticals financials

Revenue TTM	$570.9 million
Gross profit TTM	$414.8 million
Return on assets TTM	-18.17%
Return on equity TTM	-77.01%
Profit margin	-153.49%
Book value	$7.90
Market capitalisation	$21.4 billion

TTM: trailing 12 months

Shorting Alnylam Pharmaceuticals shares

There are currently 4.2 million Alnylam Pharmaceuticals shares held short by investors – that's known as Alnylam Pharmaceuticals's "short interest". This figure is 2.4% down from 4.3 million last month.

There are a few different ways that this level of interest in shorting Alnylam Pharmaceuticals shares can be evaluated.

Alnylam Pharmaceuticals's "short interest ratio" (SIR)

Alnylam Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Alnylam Pharmaceuticals shares currently shorted divided by the average quantity of Alnylam Pharmaceuticals shares traded daily (recently around 757982.58527828). Alnylam Pharmaceuticals's SIR currently stands at 5.57. In other words for every 100,000 Alnylam Pharmaceuticals shares traded daily on the market, roughly 5570 shares are currently held short.

However Alnylam Pharmaceuticals's short interest can also be evaluated against the total number of Alnylam Pharmaceuticals shares, or, against the total number of tradable Alnylam Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alnylam Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Alnylam Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0361% of the tradable shares (for every 100,000 tradable Alnylam Pharmaceuticals shares, roughly 36 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Alnylam Pharmaceuticals.

Find out more about how you can short Alnylam Pharmaceuticals stock.

Alnylam Pharmaceuticals share dividends

We're not expecting Alnylam Pharmaceuticals to pay a dividend over the next 12 months.

Alnylam Pharmaceuticals share price volatility

Over the last 12 months, Alnylam Pharmaceuticals's shares have ranged in value from as little as $119.29 up to $184.45. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alnylam Pharmaceuticals's is 1.228. This would suggest that Alnylam Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Alnylam Pharmaceuticals overview

Alnylam Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Alnylam Pharmaceuticals is owned by insiders or institutions?
Currently 0.615% of Alnylam Pharmaceuticals shares are held by insiders and 94.788% by institutions. How many people work for Alnylam Pharmaceuticals?
Latest data suggests 1,453 work at Alnylam Pharmaceuticals. When does the fiscal year end for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals's fiscal year ends in December. Where is Alnylam Pharmaceuticals based?
Alnylam Pharmaceuticals's address is: 675 West Kendall Street, Cambridge, MA, United States, 02142 What is Alnylam Pharmaceuticals's ISIN number?
Alnylam Pharmaceuticals's international securities identification number is: US02043Q1076 What is Alnylam Pharmaceuticals's CUSIP number?
Alnylam Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 02043Q107